SynthesisFrontiers in medicine2026
Efficacy and safety of hyperthermic intraperitoneal chemotherapy in treatment of primary or recurrent ovarian cancer: systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epithelial ovarian cancer (EOC) is the leading cause of mortality among gynecologic cancers. The standard treatment approach involves primary debulking surgery (PDS) followed by systemic chemotherapy. Hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as an additional therapeutic option used alongside cytoreductive surgery (CRS); however, its efficacy and safety remain controversial. Objective: This study aims to compare overall survival (OS) and progression-related outcomes between patients receiving standard multimodal treatment with intraoperative HIPEC and those receiving standard multimodal treatment without HIPEC for primary advanced or recurrent EOC, and to evaluate postoperative complications. Methods: A systematic search of Ovid-Medline, Web of Science, and PubMed was conducted without date restrictions through February 2025. Only randomized controlled trials (RCTs) were included. Two reviewers independently performed study quality assessments and data extraction. The protocol was registered in PROSPERO (CRD420251067703). Meta-analysis was conducted using fixed- and random-effects models to pool hazard ratios (HR), risk ratios (RR), and mean differences. Heterogeneity was assessed using the I Results: Six RCTs ( Conclusion: HIPEC may benefit selected patients with primary advanced EOC, particularly in trials evaluating its use during interval debulking surgery. However, the limited and heterogeneous RCT evidence warrants cautious interpretation. Systematic review registration: CRD420251067703 https://www.crd.york.ac.uk/PROSPERO/view/CRD420251067703.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.